Asthma is increasingly recognised as a heterogeneous disease, with several phenotypes defined by clinical and inflammatory characteristics. Common phenotypes include allergic (eosinophilic, IgE-mediated), non-allergic (often neutrophilic or paucigranulocytic), late-onset adult asthma, obesity-associated asthma, and asthma with persistent airflow limitation.14 Identifying phenotypes supports individualised treatment strategies, particularly in those with severe asthma, and better long-term outcomes.
Steps 2 and 3: Maintenance and reliever therapy (MART)
Comorbid conditions can complicate asthma management. Assess for and help address factors such as allergic rhinitis, which affects up to 80% of people with asthma,24 as well as gastro-oesophageal reflux disease (GORD), anxiety, depression, obstructive sleep apnoea and smoking.
Harnessing different abilities
Some might assume employing someone with a declared disability would only bring complications. But some community pharmacies around Australia are leading the way in...
Patients with COPD terrified of contracting COVID-19
After almost 2 years of the COVID-19 pandemic, pharmacists must emphasise the importance of maintaining lung health on World COPD Day (17 November).
Medicine safety – a new national priority
A watershed moment for patients, pharmacists and medicine safety was reached last week when federal, state and territory health ministers declared Medicine Safety and...
Non-steroidal care for the treatment and management of mild eczema and...
Dermal Therapy offers a comprehensive range of clinically tested products to treat and manage the symptoms associated with mild eczema and dermatitis.
Age of anxiety
Anxiety is the most common mental health condition in Australia, and research shows the pandemic has only exacerbated the issue. Are we doing enough to support those who experience it?
Resistance movement: Pharmacy’s fight against antimicrobial resistance
Antimicrobial resistance (AMR) has been ranked as serious a threat to society as terrorism. With millions of lives at risk, and trillions in GDP...
